ArticleACS omega2025
Evaluation of Antibody-Drug Conjugate Performances Using a Novel HPLC-DAD Method for Tumor-Specific Detection of DM4 and
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) are an emerging class of therapeutics that have gained interest in precision medicine for cancer treatment, combining the targeted delivery capabilities of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs. The goal is to enhance the therapeutic window by maximizing tumor cell killing while minimizing off-target toxicity. Pivotal aims are precise delivery of payload in the tumor site and a robust analytical methodology to quantify the accumulation of it. 1959-sss/DM4, a novel ADC targeting highly glycosylated LGALS3BP, which is a protein implicated in tumor progression and metastasis, was developed. This ADC has shown potent and durable antitumor activity in various preclinical models. A high-performance liquid chromatography (HPLC) method according to ICH guidelines for the simultaneous quantification of DM4 and its primary metabolite,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.